SOP: thrombolysis in ischemic stroke under oral anticoagulation therapy.

Pawel Kermer, Peter D Schellinger, Peter A Ringleb, Martin Köhrmann
{"title":"SOP: thrombolysis in ischemic stroke under oral anticoagulation therapy.","authors":"Pawel Kermer,&nbsp;Peter D Schellinger,&nbsp;Peter A Ringleb,&nbsp;Martin Köhrmann","doi":"10.1186/s42466-022-00174-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Based on demographical trends and the expected worldwide increase in the number of individuals with atrial fibrillation, the rate of patients who are on oral anticoagulation therapy for secondary prevention of stroke rises continuously. Despite correct drug intake and good adherence to the respective medication, recurrent ischemic stroke still occurs in ~ 3% of patients. The question how to deal with such patients with regard to intravenous thrombolysis with rt-PA within the 4.5 h time window is of great relevance for daily clinical routine. However, international guidelines can be considered heterogenous or do even lack recommendations on this topic especially in light of available reversal agents. Therefore, we provide this SOP.</p><p><strong>Comments: </strong>Beyond the identification of acute stroke patients on oral anticoagulation therapy, the type of medication, time since last intake, renal function and laboratory exams as well as the availability of reversal agents have to be considered before rt-PA application and potential endovascular therapy. Treatment on a Stroke Unit or Neuro-ICU is certainly recommended in any of those patients.</p><p><strong>Conclusions: </strong>This standardized operating procedure was designed to guide stroke physicians through questions on eligibility for rt-PA treatment in patients with acute ischemic stroke who are on approved oral anticoagulation therapy thereby increasing the number of patients benefitting from thrombolysis and minimizing door-to-needle times.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":" ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851794/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42466-022-00174-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Based on demographical trends and the expected worldwide increase in the number of individuals with atrial fibrillation, the rate of patients who are on oral anticoagulation therapy for secondary prevention of stroke rises continuously. Despite correct drug intake and good adherence to the respective medication, recurrent ischemic stroke still occurs in ~ 3% of patients. The question how to deal with such patients with regard to intravenous thrombolysis with rt-PA within the 4.5 h time window is of great relevance for daily clinical routine. However, international guidelines can be considered heterogenous or do even lack recommendations on this topic especially in light of available reversal agents. Therefore, we provide this SOP.

Comments: Beyond the identification of acute stroke patients on oral anticoagulation therapy, the type of medication, time since last intake, renal function and laboratory exams as well as the availability of reversal agents have to be considered before rt-PA application and potential endovascular therapy. Treatment on a Stroke Unit or Neuro-ICU is certainly recommended in any of those patients.

Conclusions: This standardized operating procedure was designed to guide stroke physicians through questions on eligibility for rt-PA treatment in patients with acute ischemic stroke who are on approved oral anticoagulation therapy thereby increasing the number of patients benefitting from thrombolysis and minimizing door-to-needle times.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SOP:口服抗凝治疗下缺血性脑卒中的溶栓。
导读:基于人口趋势和预计世界范围内房颤患者数量的增加,口服抗凝治疗用于卒中二级预防的患者比例持续上升。尽管正确的药物摄入和良好的药物依从性,仍有3%的患者发生复发性缺血性卒中。如何在4.5 h的时间窗内处理这类患者的rt-PA静脉溶栓,与日常临床常规有很大关系。然而,国际指南可能被认为是异质的,甚至缺乏关于这一主题的建议,特别是考虑到现有的逆转剂。因此,我们提供了这个SOP。评论:除了确定急性卒中患者是否接受口服抗凝治疗外,在rt-PA应用和潜在的血管内治疗之前,还必须考虑药物的类型、上一次服用的时间、肾功能和实验室检查以及逆转药物的可用性。对于这些患者,当然建议在中风病房或神经icu进行治疗。结论:该标准化操作程序旨在指导卒中医生解决接受批准口服抗凝治疗的急性缺血性卒中患者rt-PA治疗的资格问题,从而增加受益于溶栓的患者数量,并最大限度地减少从门到针的时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Resting state EEG as biomarker of cognitive training and physical activity's joint effect in Parkinson's patients with mild cognitive impairment. Camptocormia due to myotinilopathy, Parkinson's disease, or both? : Camptocormia and axial myopathy. Evolution of neurodegeneration in patients with normal pressure hydrocephalus: a monocentric follow up study. Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication. German guidelines on community-acquired acute bacterial meningitis in adults.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1